Carl Kirkwood

Dr. Carl Kirkwood

Bill and Melinda Gates Foundation, Seattle, WA 98102, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Vaccine
Verified
Journal Article
Open access
CKCarl Kirkwood
Carl Kirkwood
LMLyou-Fu Ma
Lyou-Fu Ma
MCMegan E. Carey
Megan E. Carey
DSDuncan Steele
Duncan Steele
Rotavirus disease is a leading global cause of mortality and morbidity in children under 5years of age. The effectiveness of the two globally used oral rotavirus vaccines quickly became apparent when introduced into both developed and developing countries, with significant reductions in rotavirus-associated mortality and hospitalizations. However, the effectiveness and impact of the vaccines is reduced in developing country settings, where the burden and mortality is highest. New rotavirus vaccines, including live oral rotavirus candidates and non-replicating approaches continue to be developed, with the major aim to improve the global supply of rotavirus vaccines and for local implementation, and to improve vaccine effectiveness in developing settings. This review provides an overview of the new rotavirus vaccines in development by developing country manufacturers and provides a rationale why newer candidates continue to be explored. It describes the new live oral rotavirus vaccine candidates as well as the non-replicating rotavirus vaccines that are furthest along in development.

19 November 2022 in Viruses
Verified
Journal Article
Open access
PDF file
JCJessie Chen
Jessie Chen
SGStephanie Grow
Stephanie Grow
MIMiren Iturriza-Gomara
Miren Iturriza-Gomara
WHWilliam Hausdorff
William Hausdorff
AFAlan Fix
Alan Fix
CKCarl Kirkwood
Carl Kirkwood
The 2nd Next Generation Rotavirus Vaccine Developers Meeting, sponsored by PATH and the Bill and Melinda Gates Foundation, was held in London, UK (7–8 June 2022), and attended by vaccine developers and researchers to discuss advancements in the development of next-generation rotavirus vaccines and to consider issues surrounding vaccine acceptability, introduction, and uptake. Presentations included updates on rotavirus disease burden, the impact of currently licensed oral vaccines, various platforms and approaches for next generation rotavirus vaccines, strategies for combination pediatric vaccines, and the value proposition for novel parenteral rotavirus vaccines. This report summarizes the information shared at the convening and poses various topics worthy of further exploration.

3 August 2018 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
CKCarl Kirkwood
Carl Kirkwood
DSDuncan Steele
Duncan Steele
It is well recognized that rotavirus vaccines have had an enormous impact in improving child health morbidity and reducing diarrhea-associated mortality in ever

1 December 2020 in Expert Review of Vaccines
Verified
Journal Article
Open access
CKCarl Kirkwood
Carl Kirkwood
KDKatherine R Dobscha
Katherine R Dobscha
DSDuncan Steele
Duncan Steele
Hepatitis E virus (HEV) is an important cause of enterically transmitted viral hepatitis and a significant contributor to maternal mortality in endemic regions around the world, yet the global resp...

14 October 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
PMPeter Mwangi
Peter Mwangi
Milton Tshidiso MogotsiMilton Tshidiso Mogotsi
Milton Tshidiso Mogotsi
MSMapaseka Seheri
Mapaseka Seheri
MMM. Jeffrey Mphahlele
M. Jeffrey Mphahlele
IPIna Peenze
Ina Peenze
Martin NyagaMartin Nyaga
Martin Nyaga
Rotavirus G1P[8] strains account for more than half of the group A rotavirus (RVA) infections in children under five years of age, globally. A total of 103 stool samples previously characterized as G1P[8] and collected seven years before and seven years after introducing the Rotarix® vaccine in South Africa were processed for whole-genome sequencing. All the strains analyzed had a Wa-like constellation (G1-P[8]-I1-R1-C1-M1-A1-N1-T1-E1-H1). South African pre- and post-vaccine G1 strains were clustered in G1 lineage-I and II while the majority (84.2%) of the P[8] strains were grouped in P[8] lineage-III. Several amino acid sites across ten gene segments with the exception of VP7 were under positive selective pressure. Except for the N147D substitution in the antigenic site of eight post-vaccine G1 strains when compared to both Rotarix® and pre-vaccine strains, most of the amino acid substitutions in the antigenic regions of post-vaccine G1P[8] strains were already present during the pre-vaccine period. Therefore, Rotarix® did not appear to have an impact on the amino acid differences in the antigenic regions of South African post-vaccine G1P[8] strains. However, continued whole-genome surveillance of RVA strains to decipher genetic changes in the post-vaccine period remains imperative.

21 December 2017 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
VOV. Oktaria
V. Oktaria
KLK. J. Lee
K. J. Lee
Julie Elissa BinesJulie Elissa Bines
Julie Elissa Bines
EWE. Watts
E. Watts
CSC. D. Satria
C. D. Satria
MDMargie Danchin
Margie Danchin
Infant morbidity and mortality rates remain high in Indonesia, with acute respiratory illnesses (ARI) and diarrhea the leading two health problems in children under 5 years. We aimed to describe the nutritional status, feeding practice and case management of ARI and diarrhea of infants from two regions of Indonesia during the first 6 months of life. This study was an observational study conducted in parallel to an immunogenicity and efficacy trial of an oral rotavirus vaccine (RV3-BB) in the Klaten and Yogyakarta regions, Indonesia. Mothers were interviewed at 3 time points: within the first 6 days of their infant’s life, and at 8–10 and 22–24 weeks of age. Questions asked included pregnancy history, infant nutritional status, feeding status and health of infants within up to 2 weeks prior to the assessment. Between February 2013 and January 2014, 233 mother-infant pairs were recruited. 60% (136/223) of infants were exclusively breastfed (EBF) until 6 months of age with the strongest support for EBF reported by mothers themselves 70% (101/223) and 25% (36/223) from their partners. At 6 months, 6% (14/223) of infants were underweight and severely underweight; 4% (8/ 223) wasted and severely wasted; and 12% (28/223) were stunted and severely stunted. Non-recommended medication use was high, with 54% (21/39) of infants with reported cough within 2 weeks of an assessment receiving cough medication, 70% (27 /39) an antihistamine, 26% (10/39) a mucolytic and 15% (6 /39) an oral bronchodilator. At age 22–24 week, infants with reported diarrhea within 2 weeks of an assessment had low use of oral rehydration solutions (ORS) (3/21;14%) and zinc therapy (2/ 21;10%). In this unique observational study, breastfeeding rates of 60% at 6 months were below the Indonesian national target of >75%. Adherence to WHO guidelines for management of ARI and diarrhea was poor, with high use of non-recommended cough medications and oral bronchodilators in the first 6 months of life and low use of ORS and zinc therapy. Ongoing education of primary health care workers and parents regarding management of common illness is needed in Indonesia.